RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
8.33 USD -1.65% Intraday chart for RAPT Therapeutics, Inc. +2.84% -66.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index CI
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
RAPT Therapeutics Shares Decline Following UBS Downgrade MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61 MT
North American Morning Briefing : Nvidia Ignites -2- DJ
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10 MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy MT
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15 MT
North American Morning Briefing : Stock Futures -2- DJ
Sector Update: Health Care Stocks Lower Late Afternoon MT
Top Midday Decliners MT
Stifel Cuts RAPT Therapeutics' Price Target to $33 From $40, Keeps Buy Rating MT
Piper Sandler Cuts RAPT Therapeutics' Price Target to $18 From $31, Keeps Overweight Rating MT
Cantor Fitzgerald Downgrades RAPT Therapeutics to Neutral From Overweight MT
RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold DJ
Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event DJ
FDA puts on hold two Rapt Therapeutics mid-stage drug trials RE
RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon in Atopic Dermatitis and its Phase 2a Trial in Asthma CI
Evercore ISI Starts Coverage on RAPT Therapeutics With Outperform Rating MT
Wolfe Research Starts RAPT Therapeutics With Outperform Rating, $39 Price Target MT
RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations CI
RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon to Treat Atopic Dermatitis in Allergy CI
RAPT Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart RAPT Therapeutics, Inc.
More charts
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, the Company develops selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Its two lead drug candidates each target C-C motif chemokine receptor 4 (CCR4). Its inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells) into inflamed tissues. Its lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. In addition, RPT193 has clinical translatability in a variety of inflammatory diseases beyond atopic dermatitis (AD), including allergic asthma and chronic rhinosinusitis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
8.33 USD
Average target price
22.22 USD
Spread / Average Target
+166.77%
Consensus
  1. Stock
  2. Equities
  3. Stock RAPT Therapeutics, Inc. - Nasdaq
  4. News RAPT Therapeutics, Inc.
  5. RAPT Therapeutics : Wells Fargo Hikes PT for RAPT Therapeutics to $65 From $30 on Atopic Dermatitis Treatment Results, Keeps Overweight Rating